Recombinant human C1-inhibitor in the treatment of acute angioedema attacks

Goda Choi, Maarten R. Soeters, H. Farkas, L. Varga, Krystyna Obtulowicz, Barbara Bilo, Greg Porebski, C. Erik Hack, René Verdonk, Jan Nuijens, Marcel Levi

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

BACKGROUND: Patients with hereditary C1-inhibitor deficiency have recurrent attacks of angioedema, preferably treated with C1-inhibitor concentrate. A recombinant human C1-inhibitor (rHuC1INH) was developed, derived from milk from transgenic rabbits. This study was undertaken to investigate the effects of rHuC1INH in the treatment of acute angioedema attacks in patients with a hereditary C1-inhibitor deficiency. STUDY DESIGN AND METHODS: Patients with hereditary C1-inhibitor deficiency were treated with rHuC1INH (at a dose of 100 U/kg) within 8 hours after onset of an acute attack. Time to initiation of relief and time to minimal symptoms were reported by both the patient and the treating physician. RESULTS: Thirteen severe angioedema attacks in 9 patients with hereditary C1-inhibitor deficiency were treated with rHuC1INH. There was rapid improvement of clinical conditions for all attacks, with approximately 80 percent of treated patients experiencing symptom relief within 2 hours and minimal symptoms within 12 hours. There were no drug-related adverse events or immunogenic reactions to C1-inhibitor or rabbit proteins. CONCLUSION: The transgenically produced rHuC1INH was successfully used in the treatment of acute angioedema attacks in patients with hereditary C1-inhibitor deficiency.

Original languageEnglish
Pages (from-to)1028-1032
Number of pages5
JournalTransfusion
Volume47
Issue number6
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Angioedema
Hereditary Angioedemas
Therapeutics
Rabbits
human SERPING1 protein
Drug-Related Side Effects and Adverse Reactions
Milk
Physicians

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. / Choi, Goda; Soeters, Maarten R.; Farkas, H.; Varga, L.; Obtulowicz, Krystyna; Bilo, Barbara; Porebski, Greg; Hack, C. Erik; Verdonk, René; Nuijens, Jan; Levi, Marcel.

In: Transfusion, Vol. 47, No. 6, 06.2007, p. 1028-1032.

Research output: Contribution to journalArticle

Choi, G, Soeters, MR, Farkas, H, Varga, L, Obtulowicz, K, Bilo, B, Porebski, G, Hack, CE, Verdonk, R, Nuijens, J & Levi, M 2007, 'Recombinant human C1-inhibitor in the treatment of acute angioedema attacks', Transfusion, vol. 47, no. 6, pp. 1028-1032. https://doi.org/10.1111/j.1537-2995.2007.01239.x
Choi, Goda ; Soeters, Maarten R. ; Farkas, H. ; Varga, L. ; Obtulowicz, Krystyna ; Bilo, Barbara ; Porebski, Greg ; Hack, C. Erik ; Verdonk, René ; Nuijens, Jan ; Levi, Marcel. / Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. In: Transfusion. 2007 ; Vol. 47, No. 6. pp. 1028-1032.
@article{b77a4bb81cce458085ab1c291f188e7e,
title = "Recombinant human C1-inhibitor in the treatment of acute angioedema attacks",
abstract = "BACKGROUND: Patients with hereditary C1-inhibitor deficiency have recurrent attacks of angioedema, preferably treated with C1-inhibitor concentrate. A recombinant human C1-inhibitor (rHuC1INH) was developed, derived from milk from transgenic rabbits. This study was undertaken to investigate the effects of rHuC1INH in the treatment of acute angioedema attacks in patients with a hereditary C1-inhibitor deficiency. STUDY DESIGN AND METHODS: Patients with hereditary C1-inhibitor deficiency were treated with rHuC1INH (at a dose of 100 U/kg) within 8 hours after onset of an acute attack. Time to initiation of relief and time to minimal symptoms were reported by both the patient and the treating physician. RESULTS: Thirteen severe angioedema attacks in 9 patients with hereditary C1-inhibitor deficiency were treated with rHuC1INH. There was rapid improvement of clinical conditions for all attacks, with approximately 80 percent of treated patients experiencing symptom relief within 2 hours and minimal symptoms within 12 hours. There were no drug-related adverse events or immunogenic reactions to C1-inhibitor or rabbit proteins. CONCLUSION: The transgenically produced rHuC1INH was successfully used in the treatment of acute angioedema attacks in patients with hereditary C1-inhibitor deficiency.",
author = "Goda Choi and Soeters, {Maarten R.} and H. Farkas and L. Varga and Krystyna Obtulowicz and Barbara Bilo and Greg Porebski and Hack, {C. Erik} and Ren{\'e} Verdonk and Jan Nuijens and Marcel Levi",
year = "2007",
month = "6",
doi = "10.1111/j.1537-2995.2007.01239.x",
language = "English",
volume = "47",
pages = "1028--1032",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Recombinant human C1-inhibitor in the treatment of acute angioedema attacks

AU - Choi, Goda

AU - Soeters, Maarten R.

AU - Farkas, H.

AU - Varga, L.

AU - Obtulowicz, Krystyna

AU - Bilo, Barbara

AU - Porebski, Greg

AU - Hack, C. Erik

AU - Verdonk, René

AU - Nuijens, Jan

AU - Levi, Marcel

PY - 2007/6

Y1 - 2007/6

N2 - BACKGROUND: Patients with hereditary C1-inhibitor deficiency have recurrent attacks of angioedema, preferably treated with C1-inhibitor concentrate. A recombinant human C1-inhibitor (rHuC1INH) was developed, derived from milk from transgenic rabbits. This study was undertaken to investigate the effects of rHuC1INH in the treatment of acute angioedema attacks in patients with a hereditary C1-inhibitor deficiency. STUDY DESIGN AND METHODS: Patients with hereditary C1-inhibitor deficiency were treated with rHuC1INH (at a dose of 100 U/kg) within 8 hours after onset of an acute attack. Time to initiation of relief and time to minimal symptoms were reported by both the patient and the treating physician. RESULTS: Thirteen severe angioedema attacks in 9 patients with hereditary C1-inhibitor deficiency were treated with rHuC1INH. There was rapid improvement of clinical conditions for all attacks, with approximately 80 percent of treated patients experiencing symptom relief within 2 hours and minimal symptoms within 12 hours. There were no drug-related adverse events or immunogenic reactions to C1-inhibitor or rabbit proteins. CONCLUSION: The transgenically produced rHuC1INH was successfully used in the treatment of acute angioedema attacks in patients with hereditary C1-inhibitor deficiency.

AB - BACKGROUND: Patients with hereditary C1-inhibitor deficiency have recurrent attacks of angioedema, preferably treated with C1-inhibitor concentrate. A recombinant human C1-inhibitor (rHuC1INH) was developed, derived from milk from transgenic rabbits. This study was undertaken to investigate the effects of rHuC1INH in the treatment of acute angioedema attacks in patients with a hereditary C1-inhibitor deficiency. STUDY DESIGN AND METHODS: Patients with hereditary C1-inhibitor deficiency were treated with rHuC1INH (at a dose of 100 U/kg) within 8 hours after onset of an acute attack. Time to initiation of relief and time to minimal symptoms were reported by both the patient and the treating physician. RESULTS: Thirteen severe angioedema attacks in 9 patients with hereditary C1-inhibitor deficiency were treated with rHuC1INH. There was rapid improvement of clinical conditions for all attacks, with approximately 80 percent of treated patients experiencing symptom relief within 2 hours and minimal symptoms within 12 hours. There were no drug-related adverse events or immunogenic reactions to C1-inhibitor or rabbit proteins. CONCLUSION: The transgenically produced rHuC1INH was successfully used in the treatment of acute angioedema attacks in patients with hereditary C1-inhibitor deficiency.

UR - http://www.scopus.com/inward/record.url?scp=34249025396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249025396&partnerID=8YFLogxK

U2 - 10.1111/j.1537-2995.2007.01239.x

DO - 10.1111/j.1537-2995.2007.01239.x

M3 - Article

VL - 47

SP - 1028

EP - 1032

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 6

ER -